Advertisement
Singapore markets open in 1 hour 44 minutes
  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • Dow

    38,675.68
    +449.98 (+1.18%)
     
  • Nasdaq

    16,156.33
    +315.33 (+1.99%)
     
  • Bitcoin USD

    63,957.86
    +158.91 (+0.25%)
     
  • CMC Crypto 200

    1,328.37
    +51.39 (+4.03%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Gold

    2,311.00
    +2.40 (+0.10%)
     
  • Crude Oil

    78.44
    +0.33 (+0.42%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • Nikkei

    38,236.07
    -38.03 (-0.10%)
     
  • Hang Seng

    18,475.92
    +268.82 (+1.48%)
     
  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     
  • Jakarta Composite Index

    7,134.72
    -7,117.42 (-49.94%)
     
  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

Presentation to highlight baseline characteristics of Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management

SOUTH SAN FRANCISCO, Calif., April 22, 2024--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.

In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.

ADVERTISEMENT

PES 2024 Presentation Details:

Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia
Abstract Number: 6898
Poster Session: 2
Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT
Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence

The poster will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook, and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422001816/en/

Contacts

Media Contact
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com

Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com